Novartis Targets Teva Over Myfortic Patents

By Erin Marie Daly · April 20, 2011, 4:57 PM EDT

Novartis AG accused Israeli generics maker Teva Pharmaceutical Industries Ltd. in Delaware on Wednesday of infringing a group of its patents related to immunosuppressive agent Myfortic....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Novartis AG et al v. Teva Pharmaceuticals USA Inc.

Case Number

Court

Delaware

Nature of Suit

Patent

Date Filed

April 20, 2011

Recent Articles By Erin

May 19, 2011
Genentech Sues Apotex Over Generic Valcyte
May 19, 2011
CORRECTED: Mylan's Inequitable Conduct Claim Axed In Vytorin IP Suit
May 18, 2011
Firms, Experts Allowed To Stay In AndroGel MDL
May 10, 2011
Pharmacies Attack $68B Pfizer-Wyeth Deal In 9th Circ.
May 03, 2011
2nd Circ. Rejects Nurses Review Of Class Cert. Denial
April 27, 2011
Genzyme Sues Over Endo's Bid To Sell Generic Renvela
April 27, 2011
Asahi, Actelion Throw Final Punches In Fasudil IP Row
April 13, 2011
HGS Fires Round 2 At Genentech Over Lupus Drug IP
April 13, 2011
MetroPlus, HHC Evade State Claims In OT Action
April 08, 2011
UK Court Shutters Merck's Cosopt Patent Fight